Finanzas de BeOne Medicines AG (ONC)ONCBeOne Medicines AG

BeOne Medicines AG (ONC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 96.3% of total sales, equivalent to $1.64B. Other significant revenue streams include BRUKINSA and Tislelizumab. Understanding this composition is critical for investors evaluating how ONC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, BeOne Medicines AG maintains a gross margin of 89.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.06%, while the net margin is 13.90%. These profitability ratios, combined with a Return on Equity (ROE) of 14.57%, provide a clear picture of how effectively ONC converts its operational activities into shareholder value.

In the context of the broader market, ONC competes directly with industry leaders such as MRK and NVS. With a market capitalization of $42.53B, it holds a significant position in the sector. When comparing efficiency, ONC's gross margin of 89.76% stands against MRK's 74.64% and NVS's 75.39%. Such benchmarking helps identify whether BeOne Medicines AG is trading at a premium or discount relative to its financial performance.

Beigene has shown consistent revenue growth, with total revenue reaching $1.7 billion in Q2 2026, up from $1.5 billion in Q1 2026. The net income has also improved significantly, with a net income of $237 million in Q2 2026, compared to $227 million in Q1 2026. The gross margin remains strong at 89.76%, reflecting effective cost management and pricing power.